TORONTO, April 24, 2025—BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced a new partnership with Bentham Science, a renowned science, technology, and medical publisher. 

This agreement expands BenchSci’s ASCEND platform by integrating a vast library of Bentham Science’s high-quality scientific publications, providing researchers with access to numerous closed and open-access journals across diverse therapeutic areas. Researchers focusing on cardiometabolic diseases, neuroscience, oncology, infectious diseases, and immunology will particularly benefit from this expanded access. Notably, this collaboration brings a wealth of impactful journals to ASCEND, including titles like Current Medicinal Chemistry, Current Drug Targets, Current Gene Therapy, Current Vascular Pharmacology, Current Alzheimer Research, and CNS & Neurological Disorders - Drug Targets, further empowering scientists with comprehensive and reliable information. 

BenchSci’s ASCEND platform is designed by scientists for scientists. As an AI Assistant, the platform mimics how scientists understand and extract biomedical data. It analyzes scientific publications, extracting valuable insights from both text and images to build a comprehensive, structured knowledge base. This enables scientists to efficiently uncover hidden biological connections, surface contextual evidence, and identify potential risks early. By streamlining preclinical research and prioritizing the most promising experiments, ASCEND accelerates the path to life-saving treatments. 

“In drug discovery, every experiment counts. Missed connections, overlooked data, and preventable errors can derail years of work,” said CEO and Co-founder of BenchSci, Liran Belenzon. “By providing scientists with a richer, more comprehensive view of the published landscape, we’re enabling them to identify potential pitfalls early and validate their hypotheses with greater confidence. This is about building a foundation of reliability, so scientists can focus on pushing the boundaries of what’s possible, not redoing experiments.”

"Bentham Science prioritizes the accessibility and efficient dissemination of our research content to the global scientific community," explains David Myers, North American Business Partnerships Representative at Bentham Science. "We believe that machine learning, as demonstrated by BenchSci's ASCEND technology, offers a powerful means to accelerate content discovery and biomedical research. This partnership underscores our dedication to providing researchers with the information they need to succeed." 

Access to data from Bentham Science will be available on BenchSci’s platform by the end of Q2.

About BenchSci 

BenchSci is a world leader in AI solutions for drug discovery on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. Our platform, ASCEND, acts as a scalable AI assistant for preclinical organizations, increasing the productivity of the preclinical R&D pipeline across therapeutic areas. Backed by top-tier investors, including Generation Investment Management, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We’re a Deloitte Technology Fast 50™ and Fast 500™ winner and a certified Great Place to Work®. For more information about BenchSci, visit www.benchsci.com. 

About Bentham Science

Bentham Science is a leading publisher of peer-reviewed journals and books in science, technology, and medicine, delivering the latest research to academic and industrial professionals worldwide. With a diverse portfolio of over 130 journals, Bentham Science covers pharmaceutical sciences, medical subspecialties, engineering, technology, and social sciences.

Notably, 66 Bentham Science journals received impact factor rankings in the Journal Citation Report 2023, reinforcing the publisher’s commitment to high-quality research dissemination. Through its extensive readership and global reach, Bentham Science continues to support innovation and knowledge advancement across multiple disciplines. For more information, visit benthamscience.com.

For more information, please contact Christina Peck at cpeck@benchsci.com.